Radiotheranostics Market Players:
- TransCode Therapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Clarity Pharmaceuticals
- Ariceum Therapeutics GmbH
- Novartis AG
- Bayer AG
- Progenics Pharmaceuticals, Inc.
- Telix Pharmacuticals Limited
- ITM Radiopharma
- Life Molecular Imaging
- RadioMedix
- Hitachi, Ltd.
- Chiba University
- Shimadzu Corporation
- Canon Medical System Corporation
- Toshiba Corporation
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of radiotheranostics is evaluated at USD 7.77 billion.
The global radiotheranostics market size exceeded USD 6.78 billion in 2025 and is set to register a CAGR of over 16.3%, exceeding USD 30.69 billion revenue by 2035.
North America’s radiotheranostics market will secure over 30% share by 2035, driven by increasing use of imaging technologies, precision medicine trends, and investments in cancer research.
Key players in the market include Clarity Pharmaceuticals, Ariceum Therapeutics GmbH, Novartis AG, Bayer AG, Progenics Pharmaceuticals, Inc., Telix Pharmacuticals Limited, ITM Radiopharma.
